Podcasts about PDAC

In this JCO Article Insights episode, host Jospeh Mathew summaries Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial, by Palmer, et al published December 5, 2024. Transcript Joseph Matthew: Hello and welcome to the Journal of Clinical Oncology Article Insights. I'm your host, Joseph Matthew, and today we will be discussing the article "Long-Term Survival in Resected Pancreatic Ductal Adenocarcinoma with Adjuvant Gemcitabine plus Capecitabine Compared to Modified FOLFIRINOX from the ESPAC-4 and the PRODIGE 24 Trials" by Dr. Palmer et al. To summarize the relevant evidence, the ESPAC-4 was a European phase 3 multicenter randomized clinical trial published in 2017 comparing adjuvant gemcitabine and capecitabine (GemCap) with gemcitabine monotherapy following macroscopic margin-negative resections for operable pancreatic ductal adenocarcinoma (PDAC). The trial had included non-metastatic patients aged 18 years or older, World Health Organization (WHO) performance scores of 2 or less, creatinine clearance of at least 50 mL/min, and a life expectancy of over three months who had not received any prior anticancer treatment. Patients who had undergone R2 resections were selectively excluded. Eligible participants were randomized 1:1 within 12 weeks of pancreatectomy to one of the two treatment arms, with chemotherapy initiated within two weeks from the date of randomization. The regimens involved six cycles, each lasting four weeks, for an overall duration of 24 weeks. In the monotherapy arm, gemcitabine dosed at 1 g/m² was given as an intravenous infusion once a week for three weeks, followed by one week off. In the GemCap arm, capecitabine dosed at 1660 mg/m² was added to gemcitabine, given daily for three weeks, followed by one week off. Patients were followed up every three months, with the primary endpoint being overall survival (OS). The study showed that at a median follow-up of 43.2 months, GemCap was associated with a significantly longer OS than gemcitabine alone. Subsequently, in 2018, the Phase 3 randomized PRODIGE 24 trial was conducted in centers across France and Canada, comparing adjuvant modified FOLFIRINOX (mFOLFIRINOX) with gemcitabine in a similar subset of patients with resected PDAC and reported longer OS with the mFOLFIRINOX regimen. This study, however, had more restrictive eligibility criteria when compared to ESPAC-4, including patients aged under 80 years, WHO performance status of 0 or 1, with no significant cardiovascular disease, and a postoperative serum CA 19-9 of less than 180 U/mL. There was hence a subset of ESPAC-4 patients who did not meet the eligibility criteria for mFOLFIRINOX as set by the PRODIGE 24. The present study was conducted to estimate the overall 5-year survival rates for patients of ESPAC-4 receiving GemCap and gemcitabine, further stratifying survival in either arm according to the status of the surgical margins (R status) and the resected nodes (N status), and also to investigate whether GemCap retained a survival benefit over gemcitabine in PRODIGE 24-ineligible patients. A total of 732 patients, evenly distributed between both arms, were followed up for a median period of 104 months. Adjuvant GemCap was found to retain its survival advantage over gemcitabine, with a significantly longer median OS of 31.6 months when compared to 28.4 months with gemcitabine alone. Further subgroup analysis was performed with reference to the resection margins and the nodal status. As a reminder, in the ESPAC-4 trial, 60% of patients were found to have microscopically positive margins (an R1 resection), and 80% were node-positive. The difference in survival was greater in patients undergoing microscopic margin-negative resections (R0) who experienced a median OS of 49.9 months with GemCap when compared to 32.2 months with gemcitabine. Node-negative patients also had a significantly greater 5-year OS rate with GemCap of 59% versus 53% with gemcitabine monotherapy. However, it is important to note that no significant difference in survival outcomes was observed in margin-positive (R1) or node-positive patients in the two arms. The investigators also evaluated GemCap in the subgroup of 193 patients (comprising 26.4% of the ESPAC-4 cohort) who were not considered to have met the eligibility criteria for PRODIGE 24. The survival benefit of combination therapy was retained in this group, with patients receiving GemCap experiencing a median survival of 25.9 months compared to 20.7 months with adjuvant gemcitabine. Although cross-trial comparisons have limited validity, good agreement was noted in adverse grade 3 or greater toxicity associated with the control gemcitabine arms of ESPAC-4 and PRODIGE 24, serving as the basis for a qualitative comparison of toxicities between mFOLFIRINOX and GemCap. Neutropenia was more prevalent in the GemCap arm, affecting 40.8% of patients compared to 28.4% with mFOLFIRINOX. However, granulocyte colony-stimulating factor (G-CSF) was administered to 62.2% of patients in PRODIGE 24. Palmar-plantar erythrodysesthesia (PPE) was also more prevalent with GemCap. Patients on mFOLFIRINOX were more likely to observe grade 3 or greater fatigue, diarrhea, nausea and vomiting, sensory peripheral neuropathy, and paresthesias. The investigators concluded that GemCap was the standard adjuvant treatment for patients with PDAC undergoing an upfront resection who were not feasible for mFOLFIRINOX. Further exploratory analysis revealed that patients under the age of 70 who had undergone a microscopic margin-negative (R0) resection for node-negative PDAC were likely to derive an OS benefit from the addition of capecitabine to gemcitabine in the adjuvant setting. In contrast, mFOLFIRINOX would be more effective than gemcitabine in patients with positive margins (R1) or involved nodes, as per the PRODIGE 24 trial. Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries, and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit ASCO.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Cohort study evaluated the use of ablative radiation therapy (A-RT) as a noninvasive alternative to surgery in 25 patients with technically resectable pancreatic ductal adenocarcinoma (PDAC) who were ineligible for surgery due to comorbidities. Conducted at Memorial Sloan Kettering Cancer Center between 2016 and 2022, the study found that A-RT, delivered with high precision and dose intensity, provided promising local control and overall survival, with a 2-year OS rate of 43.7% and manageable toxicity. Despite advanced age, poor performance status, and limited chemotherapy use in the cohort, outcomes suggest A-RT may be a viable local therapy for select patients with resectable PDAC, warranting further prospective investigation.Link to Arcticlehttps://jamanetwork.com/journals/jamaoncology/article-abstract/2832566

In the latest episode of The Crownsmen Show, Jerrod Downey, Roy Slack, and Rory Bamford review Refined Fool's Hazy Roy IPA and share insights on viral content, leadership myths, and the real ROI of events like PDAC and OTC.They discuss why customer-focused partnerships and purpose-driven leadership lead to success.

CME credits: 0.25 Valid until: 16-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/second-line-chemotherapy-options-in-metastatic-pdac/33136/ Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes, and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and comorbidities, which should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This two-part programme provides an overview of the different first- and second-line chemotherapy options. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Chemotherapy Strategies for Metastatic Pancreatic Ductal Adenocarcinoma

CME credits: 0.25 Valid until: 16-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/first-line-chemotherapy-options-in-metastatic-pdac/33135/ Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes, and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and comorbidities, which should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This two-part programme provides an overview of the different first- and second-line chemotherapy options. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Chemotherapy Strategies for Metastatic Pancreatic Ductal Adenocarcinoma

Glenn Jessome, President and CEO of Silver Tiger Metals (TSX.V:SLVR – OTCQX:SLVTF), joins us to unpack the key takeaways from the Swiss Mining Institute (SMI) conference, the sentiment from retail and institutional investors in Europe, the continued permitting improvements from the new political administration in Mexico, and the ongoing exploration and development work at its 100% owned, silver-gold El Tigre Project.   There appears to a be robust European appetite to invest in the precious metals and gold and silver stocks, and Glenn notes that the commodities funds as well as generalist funds are finally seeing capital inflows to invest into PM stocks.  Investors are also opening up to Mexico as a mining jurisdiction, now that more permitting progress is announced, and we recap some of the constructive comments from Fernando Aboitiz, Head of the Extractive Activities Coordination Unit, Ministry of Economy, during the Mexico Mining Forum 2025 PDAC.   Wrapping up we focus on the work the Company is continuing to do as they await their open-pit permits, where Glenn is lining up and analyzing financial term sheets for the capex needed to build the open-pit mine at El Tigre, and the company is continuing to drill from underground targeting the high-grade silver veins, and the Sulfide and Shale Zones that will feed into the upcoming PEA on the second phase of underground mining.   If you have any follow up questions for Glenn about Silver Tiger, then please email me at Shad@kereport.com.   In full disclosure, Shad is a shareholder of Silver Tiger Metals at the time of this recording, and may choose to buy or sell shares at any time.   Click here to follow the latest news from Silver Tiger Metals

Michael Steinmann, CEO of Pan American Silver, attributes record-high gold prices to global de-dollarization and central bank buying. “The fear of all these countries de-dollarizing and all the central banks that are buying gold... that's really the reason why we see that all-time high gold price happen,” he tells Daniela Cambone at the PDAC conference in Toronto in early March.Questions on Protecting Your Wealth with Gold & Silver? Schedule a Strategy Call Here ➡️ https://calendly.com/itmtrading/podcastor Call 866-349-3310

Erik Wetterling, Founder and Editor of The Hedgeless Horseman website, joins us to recap his key takeaways from the Prospectors and Developers Association of Canada (PDAC) conference in Toronto earlier this month.   He shares how he approaches getting the most out of conferences, and what kinds of questions he can ask management teams when he is in his one on one meetings. Additionally, Erik shares with us his observations on how hot trending stocks with recent newsflow got repeatedly discussed in conversations, have the more crowded booths, and saw shareprice action around the conference. Conversely, he points out how other companies with legacy projects and less regular newsflow remain not so hot, where sometimes their prior quality work has been forgotten about, and they had less of a buzz. This ties into a broader discussion on investor sentiment and herd behavior within the resource sector, the power of the network effect, and the separation of quality companies from more speculative ones as this bull market continues to pick up speed.   Click here to visit Erik's site – The Hedgeless Horseman

Send us a textDmitry Silversteyn provides his impressions of the 2025 PDAC conference in Toronto and highlights some of the hot topics attendees were discussing at this three-day event. 

In this episode from PDAC 2025, Howard provides corporate updates and market insights from players in the lithium, copper and deep-sea mining industries. CEO Gabriel Rubacha discusses Noa Lithium Brines' progress and funding status for 2025 plans, including a $13.5 million raise and confidence in fully funding their projects. Craig Shesky, CFO of the Metals Company, details their milestones in deep-sea nodules for nickel, manganese, and cobalt, underpinned by supportive US administration policies and strategic partnerships. Mitch Thomas, CEO of of Solis Minerals, outlines their transition back to copper exploration in Peru and their recent $4.5 million fundraising. CHAPTERS

In this episode at PDAC 2025, we interact with Power Metals' Chairman Johnathan More, CEO Haydn Daxter and Winsome Resources' Managing Director, Chris Evans. The discussion covers Power Metals' recent high-grade cesium discoveries, significant market growth from a 40 million to 200 million market cap, and its impact on the cesium market dominated by China. Johnathan and Haydn also address the strategic initiatives, potential for billion-dollar valuation, and plans for North American cesium industry growth. Additionally, the episode delves into cesium applications, unique mineral properties, and partnerships, including with Canaccord Genuity, aimed at advancing the company's goals. The conversation highlights the collaborative efforts with the Ontario government, indigenous partners, the future path to production as well as Winsome's investment thesis in Power Metals. CHAPTERS

  Welcome to The KE Report Weekend Show!   On this weekend's show we focus on the continued decline in US markets and recap the...

Welcome to The KE Report Weekend Show!   On this weekend's show we focus on the continued decline in US markets and recap the recent PDAC conference looking for opportunities in metals stocks.    If you enjoy the weekend show please go back through our website (https://www.kereport.com/), Podcast (https://rebrand.ly/KER-Podcast) and YouTube Page (https://www.youtube.com/@theKEReport) to listen to all our market commentary and company interviews. Please subscribe and leave us a review.   Segment 1 & 2 - Rick Bensignor, President of Bensignor Investment Strategies kicks off the show by providing a detailed analysis of the current market trends. Rick predicts potential lower targets for the S&P 500 and explains how positioning and market psychology play significant roles. He also discusses the recent performance of the US dollar, international markets, gold, and gold equities. Additionally, the conversation touches on the influence of political events and comments on the future of cryptocurrencies. Click here to visit the In The Know Trader website.   Segment 3 & 4 - Brian Leni, Editor of the Junior Stock Review, wraps up the show with a recap of the metals conferences MIF and PDAC) in Toronto over the last week and a half. We discuss what metals were the focus at the conferences (all about gold) and the types of metals stocks he is focusing on. These include select prospect generators and development plays. Click here to visit the Junior Stock Review website to keep up to date on what Brian is investing in.  

Pinnacle Silver & Gold Corp (TSX-V:PINN, OTCQB:NRGOF) president and CEO Robert Archer talked with Proactive's Stephen Gunnion about the company's latest acquisition, the El Potrero mine in Mexico. Archer explained that the company is focused on fast-tracking the project towards production within two to three years, aiming to build the business through cash flow rather than relying on external markets. El Potrero was previously in production in the late 1980s, with existing underground workings and a 100-ton-per-day processing plant. Archer highlighted that much of the infrastructure remains in place, which should help streamline redevelopment efforts at a relatively low cost. The company plans to rehabilitate the underground workings, conduct systematic sampling, and commence drilling to establish a resource base sufficient to restart production. On the financial side, Pinnacle Silver recently raised $800,000 in a private placement, with plans to secure up to $2–$3 million over the next few years to fully fund the restart. Archer also shared insights from the PDAC conference, noting positive sentiment around metals despite broader economic uncertainties. The company expects a strong news flow this year as exploration and development efforts accelerate. For more updates, visit Proactive's YouTube channel. Don't forget to like, subscribe, and turn on notifications for the latest news. #Mining #Gold #Silver #PinnacleSilver #MexicoMining #ResourceStocks #JuniorMining #GoldInvestment #MiningExploration #PreciousMetals

Bill Powers and Brian Leni share junior mining insights about PDAC, Metals Investor Forum, the multi-bagger process, and much more in this MSE episode. Bill discusses how Brian 20-bagged on Bill's loss. And Brian reveals how he lost 100% of his capital on a crooked private mining company management group. Other topics debated are whether retail investors must be bag-holders, how IR reps should not pitch companies and how to gain the human intelligence advantage in junior mining speculation. 0:00 Introduction 0:39 PDAC & Metals Investor Forum 2:36 Retail will always bag-hold? 9:32 Initial due diligence process 14:32 Human intelligence advantage 17:57 Reputation matters 23:24 Brian 20-bagged on Bill's loss 26:57 Brian's 100% loss on crooked management 31:10 People risk & uncertainty 34:01 Proper IR company pitch 35:47 Pre-production skepticism 40:10 100-bagger process 42:27 “Just hang on to hit the bull market” 44:27 Don't take credit for being lucky Brian's website: https://www.juniorstockreview.com/ Bill's Twitter: https://x.com/MiningStockEdu Sign up for our free newsletter and receive interview transcripts, stock profiles and investment ideas: http://eepurl.com/cHxJ39 Mining Stock Education offers informational content based on available data but it does not constitute investment, tax, or legal advice. It may not be appropriate for all situations or objectives. Readers and listeners should seek professional advice, make independent investigations and assessments before investing. MSE does not guarantee the accuracy or completeness of its content and should not be solely relied upon for investment decisions. MSE and its owner may hold financial interests in the companies discussed and can trade such securities without notice. MSE is biased towards its advertising sponsors which make this platform possible. MSE is not liable for representations, warranties, or omissions in its content. By accessing MSE content, users agree that MSE and its affiliates bear no liability related to the information provided or the investment decisions you make. Full disclaimer: https://www.miningstockeducation.com/disclaimer/

Ian Wagner interviews Peter Akerly of Erdene Resources at the PDAC conference in Toronto. They discuss the company's progress in gold exploration and production in Mongolia, focusing on the Bayan Khundii Gold Project and its expected output. Akerly highlights the strategic partnerships that have been formed to enhance operational efficiency. The conversation also touches on the exploration opportunities in the region and the company's future plans.

Ryan King of Calibre Mining joined MSD from the PDAC show in Toronto this week for an editorial on the reason backing the big merger news between Calibre and Equinox Gold. The conversation highlights he strategic rationale, financial aspects, leadership insights, and future growth potential of the combined entity. The discussion emphasizes the current opportunities in the gold mining sector and the expected benefits for shareholders.

Interview with Frederick H. Earnest, President & CEO, Vista Gold CorpOur previous interview: https://www.cruxinvestor.com/posts/vista-gold-tsxvgz-smaller-scale-strategy-to-enhance-economics-5520Recording date: 4th of March, 2025Vista Gold Corp is transforming its approach to developing the Mount Todd gold project in Australia, one of the world's largest undeveloped gold resources with over 9 million ounces. The company is shifting from an ambitious large-scale operation to a more financially viable smaller project that better aligns with current market realities.The original development plan called for a 50,000 tons per day operation with capital expenditure requirements of approximately $1 billion. The revised strategy reduces the scale to 15,000 tons per day with a targeted capital requirement of under $400 million—a 60% reduction in upfront investment costs."For years we talked about Mount Todd as this big project... but a billion dollars US is still a big check to write," explained Fred Earnest, President and CEO of Vista Gold, in a recent interview at the PDAC convention.While the smaller operation would produce 150,000-200,000 ounces of gold annually compared to the original plan's 500,000 ounces, the economics remain compelling. The all-in sustaining costs are estimated at $1,300 per ounce for the smaller operation, compared to $960 per ounce for the larger version, still offering substantial margins at current gold prices.A key advantage of Mount Todd is its advanced permitting status, with all necessary environmental licenses and operating permits already secured. "Literally, I think we could write a letter and we could be in construction in two or three months' time," Earnest noted.The company is well-positioned financially to advance the project, ending 2024 with approximately $17 million in cash—providing a two-year runway without additional funding. This financial stability allows Vista Gold to complete the feasibility study for the smaller-scale approach, which is expected by mid-2025.For eventual project development, Vista Gold is exploring multiple funding avenues, including Australian debt sources like the Northern Australia Infrastructure Fund and equity financing through its North American listings.The strategic pivot comes at a time when the gold mining sector faces challenges in developing new large-scale projects in safe jurisdictions. By focusing on a more manageable development approach, Vista Gold aims to position Mount Todd as an attractive opportunity for mid-tier producers seeking growth through acquisition or partnership.Learn more: https://www.cruxinvestor.com/companies/vista-gold-corporationSign up for Crux Investor: https://cruxinvestor.com

Zeus North America, Sierra Madre, Midnight Sun and Red Sea Resources, Kenmare Resources, Myriad Uranium, F3, Atlantic Lithium, Winsome Resources, Apollo Silver, Avino Silver & Gold, Mithril Silver, Guanajuato Silver, Starcore Resources

Dave Erfle, Editor of the Junior Miner Junky joins us to discuss yesterday's strong move in gold and silver stocks as opposed to the continued decline in US markets.    Despite the overall market downtrend, gold and silver stocks have shown notable strength. Dave attributes this to several factors, including a drop in the dollar and positive regulatory news from the PDAC conference regarding Mexican silver mining permits. He emphasizes the strong moves made by silver and mining stocks, highlighting that this could signal a more investible sector. Dave also points to Canadian mining's favorable conditions with a higher gold price and a weakening domestic currency.    Looking ahead Dave touches on the importance of watching trading volumes and the potential for a significant breakout in gold prices, which could further drive mining stocks.   Click here to visit the Junior Miner Junky website to learn more about Dave's investment letter.   

Fury CEO Tim Clark and QPM CEO Normand Champigny, along with Fury SVP Exploration Bryan Atkinson, explain why Fury acquiring QPM makes sense for the shareholders of both companies. Bill Powers conducted the interview at PDAC 2025. Tim Clark, CEO of Fury, commented: “This Transaction is an exciting opportunity given it doubles Fury's land package in the Eeyou Istchee territory in the James Bay Region of Quebec and unites complementary assets, teams, and investor bases which should ultimately increase shareholder value at both companies. Combining QPM's gold and critical minerals portfolio of exploration projects with Fury's projects and strong balance sheet will not only help improve cost efficiency but also add to the potential for new discoveries.” Normand Champigny, CEO and Director of QPM, commented: “We are very pleased to be entering this combination with Fury. By combining with Fury, QPM's shareholders will benefit from the synergies and cost savings of leveraging the combined company's excellent management team for funding and obtaining required permits to continue drilling at Sakami. We believe that the Transaction with Fury offers for QPM shareholders a high potential for share price appreciation in the current gold market environment. The Transaction demonstrates the progress made with our exploration work to date. Fury has the ability to rapidly advance our assets to identify a large gold mineral resource.” Sponsor: https://furygoldmines.com/ Ticker: FURY Quebec Precious Metals: https://www.qpmcorp.ca/en/ Press Releases discussed: https://furygoldmines.com/fury-gold-mines-limited-to-acquire-quebec-precious-metals-corporation/ 0:00 Intro 0:51 Rationale for Fury's acquisition of QPM 2:53 QPM's Sakami gold project 3:47 QPM's Kipawa REE project 5:17 Fury to “focus on gold in James Bay” 6:31 Normand Champigny will be Fury advisor 7:19 Eleonore South drilling ongoing 7:43 Major interest in Committee Bay project 8:18 BMO & PDAC: “a lot of excitement” Sign up for our free newsletter and receive interview transcripts, stock profiles and investment ideas: http://eepurl.com/cHxJ39 Sponsor Fury Gold Mines pays MSE a United States dollar seven thousand per month coverage fee. The forward-looking statement found in Fury Gold's most-recent presentation found at www.FuryGoldMines.com applies to everything discussed in this interview. Mining Stock Education (MSE) offers informational content based on available data but it does not constitute investment, tax, or legal advice. It may not be appropriate for all situations or objectives. Readers and listeners should seek professional advice, make independent investigations and assessments before investing. MSE does not guarantee the accuracy or completeness of its content and should not be solely relied upon for investment decisions. MSE and its owner may hold financial interests in the companies discussed and can trade such securities without notice. MSE is biased towards its advertising sponsors which make this platform possible. MSE is not liable for representations, warranties, or omissions in its content. By accessing MSE content, users agree that MSE and its affiliates bear no liability related to the information provided or the investment decisions you make. Full disclaimer: https://www.miningstockeducation.com/disclaimer/

Ian Wagner interviews Fabian Baker from Kingsrose Mining at the PDAC conference. They discuss the company's strategic focus on exploration opportunities, particularly the acquisition of the Jakon project in Finland and the ongoing partnership with BHP. Baker elaborates on the unique structure of their alliance with BHP, which allows for significant funding without equity dilution. The conversation also covers the Penikat project, highlighting its potential as a high-grade PGE resource, and concludes with insights into the company's acquisition strategy and future prospects.

National Stock Exchange of Australia CEO Max Cunningham talked with Proactive's Angela Harmantas from the PDAC conference in Toronto about the exchange's role in the Australian market, its focus on mining companies, and its expansion plans. Cunningham explained that the NSX is one of two active stock exchanges in Australia with a tier-one license, allowing it to serve all investors, including retail. He highlighted that around one-third of the exchange's listings are mining-related, with strong growth potential in the sector. Cunningham noted that NSX is working to fill a gap in the Australian venture market and is focusing on attracting mining companies, especially from regions like Perth. He also emphasized the importance of international relationships, mentioning cross-listing agreements with Canadian exchanges such as the CSE and TSX, as well as OTC Markets. Looking ahead to 2025, Cunningham discussed the challenges of IPOs due to regulatory hurdles and capital-raising difficulties. Instead, the NSX is prioritizing direct listings, which allow companies to go public without raising capital upfront. He stated that NSX is seeing increased interest from firms moving from the incumbent Australian exchange, as well as from Canadian companies seeking dual listings. #NSX #StockMarket #MiningStocks #IPOs #DirectListings #PDAC2025 #Investing #AustralianMarkets #DualListings #CapitalMarkets

Lavras Gold Corp. President & CEO Michael Durose talked with Proactive's Angela Harmantas from the PDAC conference on Toronto about the company's latest developments at the Lavras do Sul (LDS) Project in Brazil. The company, a gold exploration firm, currently holds around 1 million ounces across two of 24 exploration targets. Durose outlined the key 2024 milestones, including 17,000 meters of drilling across key areas such as Butiá, Fazenda do Posto, and Caneleira. A major highlight was the Almeria discovery, where drilling intersected 56 meters at 1 gram per ton of gold from surface. Looking ahead, Lavras Gold is focused on infill drilling at Butiá to define a potential mineable resource and step-out drilling at Fazenda do Posto to determine the mineralization limits. The company is also conducting metallurgical test work at Butiá, which will later extend to Fazenda do Posto. Durose emphasized that additional drilling results and exploration at Caneleira will be major catalysts for the company in 2024, potentially expanding the known mineralization footprint. #LavrasGold #GoldExploration #MiningNews #GoldStocks #BrazilMining #JuniorMining #DrillResults #GoldDiscovery #Investing #MiningInvestments

El ex director del FMI, Claudio Loser, comentó acerca de cuáles podrían ser los problemas actuales en la negociación del nuevo acuerdo con el FMI: “Creo que está muy avanzado en la parte fiscal monetaria, no veo ningún problema. Yo veo problemas en cuanto a fechas para salir del cepo. Y la otra cosa es que el fondo le debe decir a la Argentina ustedes no se gasten el dinero que nosotros les damos. Mi ley dijo que no era aumento de deuda, eso es mirándolo desde el gobierno central. Pero si juntamos el banco central con el gobierno, que es lo que el fondo hace, lo que el fondo está haciendo es dándole un préstamo y no quiere que se gaste. Eso es lo que deben estar peleando”. Respecto al deseo del fondo de salir del CEPO, Loser dijo: “Evidentemente el fondo quiere que se salga del cepo, el fondo quiere, supongo que quiere que el tipo de cambio sea diferente, eso es demasiado, eso no creo que sea algo que el fondo le vaya a decir inmediatamente”.Carlos Pagni mostró un gráfico sobre el problema de competitividad de los salarios en dólares: “Relación de amistad con Milei, que es el tema del salario en dólar los salarios en dólares en esta época de este dm2 de esta salida que son en el en el dólar blue 1405 dólares y 1091 dólares ahora miren la suba desde noviembre diciembre del 23 enero del 24 hasta ahora el repunte de los salarios en dólares que plantean un problema de competitividad”.Guillermo Francos opinó acerca de las declaraciones del Presidente Trump sobre un posible acuerdo de libre comercio entre ambos países: “Yo creo que el Presidente Trump expresó un apoyo explícito allí en Estados Unidos, lo volvió a expresar después, ya cuando el Presidente Milei estaba acá en la Argentina. Yo creo que hay una sintonía muy importante que va a servir para muchas cosas, entre otras puede servir para conseguir el apoyo también en el tratamiento del acuerdo que está muy avanzado, ¿no? Así que por supuesto que Estados Unidos es decisivo en estos temas, es muy importante su apoyo y seguramente el Presidente Milei lo va a obtener”.Donald Trump afirmó sobre las políticas de diversidad e inclusión: “Hemos acabado con la tiranía de las políticas de diversidad, equidad e inclusión a través de todo el gobierno federal y, de hecho, del sector privado y de nuestra militaria. Y nuestro país no será más abierto. Creemos que, sin importar si eres un médico, un accionista, un abogado o un controlador de tráfico de aire, deberías ser contratado y promovido basado en habilidad y competencia, y no en raza o género”.En su discurso en la exposición PDAC 2025 en Canadá, Karina Milei agradeció y manifestó el deseo de que inviertan en el país: “Estoy muy feliz de haber participado de un montón de encuentros en el marco de la FIDAN. He logrado el objetivo de demostrar el apoyo que tiene el gobierno de Natalia Milay para la Secretaría de Minería y todo su equipo económico. Este gobierno trabaja día a día por hacer una economía más estable, más abierta al mundo y, por supuesto, más atractiva para inversiones. En esta nueva Argentina están todos bienvenidos para que vengan y hagan sus inversiones y tengan seguro que esta Argentina va a cumplir con todo lo que se pacte”.Noticias del miércoles 5 de marzo por María O'Donnell y el equipo de De Acá en Más por Urbana Play 104.3 FMSeguí a De Acá en Más en Instagram y XUrbana Play 104.3 FM. Somos la radio que ves. Suscribite a #Youtube. Seguí a la radio en Instagram y en XMandanos un whatsapp ➯ Acá¡Descargá nuestra #APP oficial! ➯ Android ➯ iOS

Watch on YouTube At the PDAC 2025 convention in Toronto, Martin Walter, CEO of Carlton Precious Metals (TSX-V: CPI), discusses the company's flagship Esquilache Silver Project in Peru. With a background in major silver transactions, including the sale of Aquiline Resources, Walter highlights Esquilache's high-grade silver, gold, and base metals, positioning CPI well in the current silver bull market.

Ivan Bebek, Chair and CEO, commented, ““Drilling to date has been completed under budget and on time, and is continuously providing valuable insights into our thesis that a large, mineralized skarn system could be present. Our knowledge of the controls of the system and the vectoring towards key mineralized areas of the skarn continues to improve, while programs have also identified new robust targets for discovery. The identification of the Tipicancha and Antapampa targets are significant as they also offer prospective targets with scale for considerable copper-gold discoveries at Sombrero. With a 100,000-hectare land position, we have barely scratched the surface of this district.” Coppernico has successfully completed approximately 7,100 m of drilling to date having recently commenced hole 18, with ongoing work focusing on key targets within the Ccascabamba target area. Sponsor: https://coppernicometals.com/ Press Release discussed: https://coppernicometals.com/coppernico-provides-update-on-drilling-and-new-epithermal-and-skarn-targets/ TSX:COPR; OTCQB: CPPMF 0:00 Intro 0:39 “We found two more skarn targets” 1:58 “Next three holes are the most exciting” 3:46 Market commentary 5:40 New targets 6:40 Ivan looking to buy copper projects 8:29 Exploration pace 10:07 Treasury management 11:41 “Timing of discovery is so critical” Sign up for our free newsletter and receive interview transcripts, stock profiles and investment ideas: http://eepurl.com/cHxJ39 Sponsor Coppernico Metals pays MSE a United States dollar seven thousand per month coverage fee. Mining Stock Education (MSE) offers informational content based on available data but it does not constitute investment, tax, or legal advice. It may not be appropriate for all situations or objectives. Readers and listeners should seek professional advice, make independent investigations and assessments before investing. MSE does not guarantee the accuracy or completeness of its content and should not be solely relied upon for investment decisions. MSE and its owner may hold financial interests in the companies discussed and can trade such securities without notice. MSE is biased towards its advertising sponsors which make this platform possible. MSE is not liable for representations, warranties, or omissions in its content. By accessing MSE content, users agree that MSE and its affiliates bear no liability related to the information provided or the investment decisions you make. Full disclaimer: https://www.miningstockeducation.com/disclaimer/

Atlantic Lithium

F3 Uranium

Jindalee Lithium Ltd (ASX:JLL, OTCQX:JNDAF) CEO Ian Rodger talked with Proactive about the company's McDermitt project, a large-scale lithium resource on the Oregon-Nevada border. The project is among the most advanced sedimentary lithium assets in the US. Rodger discussed the company's recent pre-feasibility study, highlighting its potential as a multi-generational, low-cost source of battery-grade lithium. He also addressed the company's recent asset sale, which generated approximately 3 million AUD. Rodger emphasized Jindalee's long-standing strategy of creating shareholder value through exploration success, joint ventures, and asset sales. With a strong financial position, the company aims to progress key catalysts in 2025, including a Department of Defense grant application and permitting milestones. Rodger also noted the company's discussions with potential partners to fund the next development stage of the McDermitt project. He stated, "We're positioning the company for success in 2026, with key funding and strategic milestones ahead." For more interviews and updates, visit Proactive's YouTube channel. Don't forget to like, subscribe, and turn on notifications! #JindaleeLithium #LithiumMining #BatteryMetals #EVRevolution #MiningStocks #LithiumSupply #EnergyTransition #CriticalMinerals #Investing #PDAC2025

Sayona Mining Ltd Managing Director & CEO Lucas Dow talked with Proactive about the company's growth strategy and key priorities for 2025. He highlighted that Sayona Mining is currently North America's largest spodumene producer, with over 200,000 tonnes produced annually at its North American Lithium (NAL) facility. The company also has its Moblan project, a greenfield development in partnership with Investment Quebec. Dow discussed the strategic rationale behind Sayona's merger with Piedmont Lithium, announced in November 2024. He noted that extensive exploration at NAL had significantly increased the resource base, making an expansion possible. However, an existing offtake agreement with Piedmont posed challenges, which the merger resolves. Sayona expects operational synergies from the merger to generate cost savings of between $15 million to $20 million per year. For 2025, the company's key priorities include reducing unit costs, optimizing production, and achieving cash break-even. Additionally, Sayona is focused on completing the merger by mid-year and progressing both brownfield expansion at NAL and development at Moblan. Dow emphasized the company's commitment to efficiency and growth, stating, "We're really quite excited about the opportunity this move is going to provide." For more updates on Sayona Mining, visit Proactive's YouTube channel. Don't forget to like this video, subscribe, and turn on notifications for future content. #SayonaMining #Lithium #MiningStocks #BatteryMetals #EVRevolution #PiedmontLithium #Spodumene #Investing #MiningIndustry #PDAC2025

Millennial Potash Corp (TSX-V:MLP, OTCQB:MLPNF) is advancing its Banio Potash Project in Gabon, leveraging extensive historical data and significant resource potential. Speaking at the PDAC conference in Toronto, Chairman Farhad Abasov shared key updates with Proactive's Angela Harmantas, highlighting the project's economic viability, strategic location, and government support. A recently completed economic assessment confirmed a 1.7 billion tonne indicated and inferred resource estimate, reinforcing the project's scale and cost competitiveness. Abasov emphasized Banio's proximity to major agricultural markets such as Brazil, India, China, and Africa, ensuring strong demand for its potash production. Gabon's mining reforms have strengthened the project's outlook, with the government actively supporting the Banio Project. Abasov noted a recent visit from the country's president, signaling confidence in its economic and strategic value. Key milestones for 2024 include ongoing environmental studies, a second phase of drilling to expand the resource base, and the initiation of a feasibility study, which will run parallel to environmental assessments and is expected to conclude by early 2025. With strong backing, a large resource base, and a clear path to development, Millennial Potash is positioning itself as a major future supplier of potash, supporting global food security while contributing to Gabon's economic growth. #tsxv #mlp #otcqb #mlpnf MillennialPotash #PotashMining #GabonMining #BanioProject #MiningInvestment #NaturalResources #MiningStocks #Commodities #SustainableMining #ProactiveInvestors

Our lead story: Indigenous reaction to U.S. President Donald Trump's 25% tariffs against Canadian and Mexican imports, set to take effect today. . . . . . . . . . Interstitial: zapsplat.com

“If you just appreciate what this sector does once momentum gets started. Look at any historic junior chart, once momentum starts it just feeds on itself. What is weird is that it has not really happened; not even gold to three thousand [dollars] has been able to do that. I also think it points to how irrational this sector is. And it is all about momentum,” says private investor Erik Wetterling in this MSE episode. Erik, furthermore, shares his current views on the junior mining sector and how he is managing his portfolio. 0:00 Introduction 0:55 Junior mining value opportunities 5:53 When will gold stocks respond? 14:18 Fort Knox gold audit 18:42 Speculation in non-gold metals 21:54 Separating signal from noise 27:06 PDAC expectations 31:44 Networking necessity 34:21 Stock picks 39:17 Why retail loses money Erik's website: https://www.thehedgelesshorseman.com/ Sign up for our free newsletter and receive interview transcripts, stock profiles and investment ideas: http://eepurl.com/cHxJ39 Mining Stock Education (MSE) offers informational content based on available data but it does not constitute investment, tax, or legal advice. It may not be appropriate for all situations or objectives. Readers and listeners should seek professional advice, make independent investigations and assessments before investing. MSE does not guarantee the accuracy or completeness of its content and should not be solely relied upon for investment decisions. MSE and its owner may hold financial interests in the companies discussed and can trade such securities without notice. If you buy stock in a company featured on MSE, for your own protection, you should assume that it is MSE's owner personally selling you that stock. MSE is biased towards its advertising sponsors which make this platform possible. MSE is not liable for representations, warranties, or omissions in its content. By accessing MSE content, users agree that MSE and its affiliates bear no liability related to the information provided or the investment decisions you make. Full disclaimer: https://www.miningstockeducation.com/disclaimer/

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce positive final overall survival data from the company's Phase 2 clinical trial of its investigational immunotherapy combined with an antiviral agent and standard-of-care (SoC) chemoradiation, followed by surgery, in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC). The updated results, reflecting an additional nine months of follow-up, demonstrated a durable survival advantage for patients receiving the combination therapy plus SoC compared to SoC alone. Patients treated with the investigational immunotherapy (n=7) achieved an estimated median overall survival of 31.4 months after enrollment, significantly longer than the 12.5 months observed in the control group (n=6). Notably, long-term survivors in the immunotherapy group—alive at 66.0, 63.6, and 35.8 months post-enrollment—experienced disease recurrence but responded to salvage chemotherapy, leading to prolonged post-progression survival, further underscoring the therapy's sustained benefits. Dr. Tak emphasized that pancreatic cancer remains one of the most challenging diseases to treat, as patients with borderline resectable PDAC often harbor undetectable metastases not cleared by current neoadjuvant chemoradiation and surgery. The investigational immunotherapy, designed to stimulate an in situ vaccine-like response against the patient's tumor, shows potential to improve long-term outcomes and extend survival in this aggressive cancer setting. The U.S. Food and Drug Administration (FDA) has previously granted the therapy Fast Track and Orphan Drug Designations in combination with the antiviral agent for the treatment of PDAC, supporting its expedited development as a promising new treatment option for this devastating disease. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

In this episode, Haydn and Nigel discuss Power Metal's (TSXV: PWM | OTCQB: PWRMF) rare high-grade cesium discoveries, specifically the Case Lake project. They delve into the cost, timelines, and permitting processes compared to other critical minerals like lithium. The conversation includes updates on cesium carbonate market size (2,200 tons per year) and OPEX costs, exploration updates like cesium oxide intercepts greater than 20% in phase three drilling, and test work progress at SGS and Nagrom. The discussion also covers structural mapping exercises, upcoming exploration plans starting in March, and engagement with Canaccord for strategic guidance. They aim to fast-track mining operations and place Power Metals among the top four producers of high-grade cesium, with milestones such as the mineral resource estimate due by the end of Q1 and the PEA by the end of Q2. CHAPTERS

In today's episode, supported by Revolution Medicines, we had the pleasure of speaking with Heinz-Josef Lenz, MD, about RAS mutations in pancreatic ductal adenocarcinoma (PDAC). Dr Lenz is a professor of medicine at the Keck School of Medicine of the University of Southern California (USC), as well as the J. Terrence Lanni Chair in Gastrointestinal Cancer Research, co-director of the USC Center for Molecular Pathway and Drug Discovery, and co-director of the USC Norris Center for Cancer Drug Development in Los Angeles. In our exclusive interview, Dr Lenz discussed the prevalence of RAS mutations in PDAC, the importance of biomarker testing, current treatment strategies for patients with RAS-mutant PDAC, and potential future treatment advances for patients with this disease.

This week's podcast features Jeff Killeen, Director of Policy & Programs at PDAC, in conversation with host Adrian Pocobelli. They dive into the upcoming PDAC conference in Toronto and explore key mining policy issues in Canada. Killeen sheds light on some of the major topics impacting the Canadian mining sector, including the challenges posed by the Alternative Minimum Tax (AMT) and the upcoming expiration of the Mineral Exploration Tax Credit (METC) in March. He also offers insights into potential solutions aimed at streamlining mineral production and processing across the country. All this and more with host Adrian Pocobelli. Music Credits “Rattlesnake Railroad”, “Big Western Sky”, “Western Adventure” and “Battle on the Western Frontier” by Brett Van Donsel (⁠www.incompetech.com⁠). Licensed under Creative Commons: By Attribution 4.0 License ⁠creativecommons.org/licenses/by/4.0⁠ Apple Podcasts:⁠ https://podcasts.apple.com/ca/podcast/the-northern-miner-podcast/id1099281201⁠ Spotify:⁠ https://open.spotify.com/show/78lyjMTRlRwZxQwz2fwQ4K⁠ YouTube:⁠ https://www.youtube.com/@NorthernMiner⁠ Soundcloud:⁠ https://soundcloud.com/northern-miner

Ewan Downie's career in the mining industry spans over 25 years, marked by remarkable success in company-building, major discoveries, and accretive acquisitions. As the former CEO of i-80 Gold Corp, President and CEO of Premier Gold Mines, and CEO of Wolfden Resources Corporation, Downie led these companies through transformative stages, culminating in high-value takeover transactions. Notably, he orchestrated the acquisition of the Hardrock gold project from Barrick Gold for just $3 million, a move that would later become the flagship asset for Equinox Gold. In addition to his leadership roles, Downie was awarded the 2003 Bill Dennis Prospector of The Year by the PDAC for his major polymetallic base metal discovery in Canada, further cementing his reputation as one of the industry's foremost visionaries. TRANSITIONING TO VENTURE CAPITAL: GIANT VENTURE CAPITAL'S AMBITIOUS STRATEGY Now, as the Principal at Giant Venture Capital, Downie is channeling his expertise into high-growth exploration opportunities. In this exclusive interview with AGORACOM Founder George Tsiolis, Downie shares how his extensive mining experience and success in acquisitions are informing his new venture, which aims to identify and develop undervalued grassroots projects with massive upside potential. Downie reveals that his team is already working on projects with mining giants like Glencore and is exploring new opportunities in Nevada and other high-potential jurisdictions. STRATEGIC VISION FOR THE FUTURE OF EXPLORATION AND MINING CAPITAL Giant Venture Capital's strategy is simple but powerful: identify and develop undervalued, advanced grassroots projects with a clear path to commercialization. Downie's team plans to launch one new company per year, with a strong focus on leveraging technological advances, including AI-driven exploration, to accelerate discovery and improve efficiency in the field. ADDRESSING CHALLENGES IN CANADIAN MINING AND LOOKING AHEAD During the conversation, Downie also discusses the challenges currently facing the Canadian mining sector, from regulatory hurdles to strained relations with First Nation communities. He advocates for a more business-friendly approach to permitting, which could unlock faster approvals and drive industry growth. Despite the sector's cyclical challenges, Downie remains optimistic about the future of exploration and the potential for venture capital to play a transformative role. THE ROAD AHEAD: A BRIGHT FUTURE FOR MINING EXPLORATION Downie's transition to venture capital is backed by his deep understanding of the mining sector, a proven ability to identify value, and a strategic vision that incorporates the latest technological advancements. As he continues to build Giant Venture Capital, he remains committed to discovering the next big mining opportunity—and investors with an eye on high-growth, long-term potential should keep a close watch on this evolving story.

CME credits: 0.25 Valid until: 13-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnosis-and-management-of-metastatic-pdac/26434/ Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and co-morbidities and these should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This 2-part microlearning provides an overview of the risk factors, diagnostic tools and treatment options available to date for different patient groups. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

CME credits: 0.25 Valid until: 13-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/chemotherapy-strategies-for-metastatic-pdac/26435/ Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and co-morbidities and these should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This 2-part microlearning provides an overview of the risk factors, diagnostic tools and treatment options available to date for different patient groups. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

Guest: Efrat Dotan, MD Guest: Shubham Pant, MD, MBBS Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and co-morbidities and these should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This 2-part microlearning provides an overview of the risk factors, diagnostic tools and treatment options available to date for different patient groups. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

Guest: Efrat Dotan, MD Guest: Shubham Pant, MD, MBBS Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and co-morbidities and these should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This 2-part microlearning provides an overview of the risk factors, diagnostic tools and treatment options available to date for different patient groups. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

In this episode of SurgOnc Today®, Dr. Julie Hallet, Chair of the HPB Disease Site Work Group, and Dr. Patricio Polanco, Vice-Chair of the HPB Disease Site Work Group, are joined by Drs. Sajid Khan from Yale School of Medicine and Dr. Cecilia Ethun from UT Southwestern. They will wrap the 2024 HPB year by reviewing the top HPB surgical oncology published this year.  References/Resources: #10: AMPLIFY https://www.nature.com/articles/s41591-023-02760-3   #9: Adjuvant therapy for IPMN-derived PDAC - https://ascopubs.org/doi/abs/10.1200/JCO.23.02313   #8: HELIX https://jamanetwork.com/journals/jama/fullarticle/2822555  #7: CAMINO  https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00572-7/fulltext  #5 : PANDAS/PRODIGE https://www.annalsofoncology.org/article/S0923-7534(24)03884-5/fulltext

In a conversation with CancerNetwork® during Pancreatic Cancer Awareness Month, Tanios S. Bekaii-Saab, MD, spoke about various developments in the pancreatic cancer treatment field. Throughout the discussion, Bekaii-Saab weighed the benefits of currently available chemotherapeutic regimens for patients with metastatic disease, discussed research on the potential for precision medicine in those with KRAS wildtype pancreatic ductal adenocarcinoma (PDAC), and detailed ongoing initiatives to improve outcomes among those with RAS mutations and other targetable genomic alterations. Bekaii-Saab is the David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research, chair and consultant in the Division of Hematology and Medical Oncology at Mayo Clinic in Arizona, and co-leader of Advanced Clinical and Translational Science at Mayo Clinic Cancer Center. Given the prevalence of RAS mutations and other alterations in patients with pancreatic cancer, Bekaii-Saab especially emphasized the use of genomic analysis to inform personalized treatment decision-making in the field. Screening patients to detect aberrations such as microsatellite instability-high tumors, BRAF 600E mutations, KRAS G12C mutations, and NRG1 fusions can open the door for the development and use of targeted agents, which may consequently improve patient outcomes.  Looking ahead, Bekaii-Saab noted the need to adapt the therapies that have shown activity in the later stages of the disease to earlier treatment settings. Although “great work” has been achieved with chemotherapy and surgical techniques, he highlighted the importance of bringing targeted agents to earlier lines of therapy to further increase the likelihood of positive outcomes for patients.  “I have never been more optimistic. I'm always the eternal optimist, but I'm even more optimistic today that we're going to move the needle for our patients with pancreatic cancer and continue to enhance that likelihood of living longer, having a better quality of life, or even increasing the level of a cure for this cancer,” Bekaii-Sabb stated. “Certainly, the future looks bright. We're chipping away, one drug at a time. We can now remove that whole concept of nihilism in pancreatic cancer and look quite optimistically on the future.”

BUFFALO, NY- July 10, 2024 – A new #editorial paper was #published in Oncotarget's Volume 15 on June 20, 2024, entitled, “Targeting ABC transporters in PDAC – past, present, or future?” In this new editorial, Cecilia Bergonzini, Elisa Giovannetti and Erik H.J. Danen from Leiden University discuss targeting ABC transporters in pancreatic ductal carcinoma (PDAC). Despite its lower incidence as compared to more common cancers such as lung or breast carcinomas, PDAC ranks as the third leading cause of cancer mortality in the US and the sixth worldwide. This is due to the fact that PDAC survival rates are among the lowest for cancer patients, around 13% in the US. ATP-binding cassette (ABC) transporters represent a family of transmembrane proteins that, using the energy from ATP hydrolysis, extrude molecules from the cytoplasm to the exterior or into vesicles. Some of these transporters have been associated with resistance to a spectrum of structurally diverse chemotherapeutic drugs, earning them the name of multidrug resistance (MDR) pumps. One of the best-characterized ABC transporters is ABCB1 (MDR1). It is physiologically expressed in tissues such as kidney, liver, pancreas, intestine, the blood-brain barrier, and more, where it exerts a protective role, by extruding xenobiotics and potentially toxic molecules. Moreover, increased ABCB1 expression in tumors has been associated with poor prognosis. “Paclitaxel is a bona fide substrate for ABCB1 [18] and ABCB1 has been implicated in paclitaxel and nab-paclitaxel resistance in multiple types of cancer [19, 20]. Could ABCB1 represent a therapeutic target in PDAC patients to suppress resistance against GnP? We have recently reported that ABCB1 can indeed play a critical role in paclitaxel resistance in PDAC cells [21].” DOI - https://doi.org/10.18632/oncotarget.28597 Correspondence to - Erik H.J. Danen - e.danen@lacdr.leidenuniv.nl Video short - https://www.youtube.com/watch?v=safa58X8NMY Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28597 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, PDAC, chemoresistance, ABCB1 About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Seasoned resource fund manager Warren Irwin returns to MSE to talk mining scams: “There really is no penalties for scamming people in Canada in the mining sector. I cannot think of a single person that has done any jailtime. They may get fines or slap on the wrist or not being allowed to be a director or whatever. If you are into organized crime, get into the mining business because there is no penalties and there is lots of money to be made.” Warren also discusses his current mining stock holdings and explains why he sold NexGen Energy: “I know way more than I could every say.” 0:00 Intro 0:43 Reflecting on the Bre-X scam 9:21 Realizing Bre-X was a scam 12:38 Tenacious due diligence 18:25 “When are you going to twin the holes?” 20:31 Michael de Guzman alive?! 26:50 People complicit with the fraud 33:34 “There is no penalties for scamming people in Canada” 37:03 Warren's Solaris Resources' commentary 40:00 Selling NexGen: “I know way more than I could ever say” 42:45 Addressing Uranium super-bulls 47:24 Are you shorting NexGen? 48:48 Current mining stock holdings Warren's fund: https://www.rosseau.com/ Warren's Twitter: https://twitter.com/bigdude6669 To learn about Warren's first-hand experience with the Bre-X mining scam of the 90's listen to our in-depth interview from PDAC 2018: http://www.miningstockeducation.com/2018/04/warren-irwin-discerning-mining-stock-scams-from-bre-x-until-today-top-hedge-fund-manager-shares-insights-pdac-2018/ Warren's Bre-X article: https://ceo.ca/@warrenirwin/2016s-top-hedge-fund-manager-relives-historys-greatest-gold-scam BBC Bre-X podcast: https://www.cbc.ca/listen/cbc-podcasts/1428-the-six-billion-dollar-gold-scam/episode/16069066-episode-1-the-dollar6-billion-gold-scam Sign up for our free newsletter and receive interview transcripts, stock profiles and investment ideas: http://eepurl.com/cHxJ39 Mining Stock Education (MSE) offers informational content based on available data but it does not constitute investment, tax, or legal advice. It may not be appropriate for all situations or objectives. Readers and listeners should seek professional advice, make independent investigations and assessments before investing. MSE does not guarantee the accuracy or completeness of its content and should not be solely relied upon for investment decisions. MSE and its owner may hold financial interests in the companies discussed and can trade such securities without notice. MSE is biased towards its advertising sponsors which make this platform possible. MSE is not liable for representations, warranties, or omissions in its content. By accessing MSE content, users agree that MSE and its affiliates bear no liability related to the information provided or the investment decisions you make. Full disclaimer: https://www.miningstockeducation.com/disclaimer/

Did you know that Alta Copper (TSX: ATCU | OTCQX: ATCUF | BVL: ATCU) is well-connected with Peru's pro-mining government? Get the inside scoop on Alta Copper's productive meetings with Peru's Energy and Mines Minister Rómulo Mucho and his team during PDAC 2024 in this exclusive interview with Executive Chair and Director Giulio Bonifacio.Alta Copper is gearing up for an exciting year with upcoming catalysts, including an updated preliminary economic assessment and a 10,000-meter drilling program. With nearly $10 million in capital raised in 2023, Alta Copper's solid financials position it for growth in the booming copper mining industry.Don't miss out on the latest Alta Copper news and developments-- visit https://altacopper.comWatch the full YouTube interview here: https://youtu.be/-SXs3pdxdzYAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1